Pfizer Criticized Over Patent Strategy for COVID-19 Pill, Despite a Deal To Broaden Access in Poor Countries

“Pfizer has attempted to paint a positive picture of its MPP license despite its many restrictions,” Professor Brook Baker ’76, senior policy analyst for Health GAP, tells STAT. “It doesn’t advertise that it has reserved 46% of the world’s population – people from high- and upper-middle-income countries – for its exclusive sales.”